New drug shows promise for Hard-to-Treat cancers in early trial

NCT ID NCT05109975

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 31 times

Summary

This early-phase study is testing a new drug called Debio 0123 in 66 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the safest and most effective dose and to see if the drug can shrink tumors. Participants receive the drug alone, and the study monitors side effects and tumor response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Clinica Universidad de Navarra

    Madrid, 28027, Spain

  • Clinica Universidad de Navarra

    Pamplona, 31008, Spain

  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center

    New York, New York, 10021, United States

  • Froedtert Hospital and the Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • Hospital Clinico Universitario de Valencia

    Valencia, 46010, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, 08035, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • Hospital Universitario La Paz

    Madrid, 28046, Spain

  • Institut Catala de Oncologia

    Girona, 17007, Spain

  • Istituto Oncologico della Svizzera italiana - Ente Ospedaliero Cantonale

    Bellinzona, 6500, Switzerland

  • Kantonsspital St. Gallen, Rorschacher Strasse 95

    Sankt Gallen, 9007, Switzerland

  • START Madrid. Hospital Fundación Jimenez Diaz

    Madrid, 28040, Spain

  • South Texas Accelerated Research Therapeutics (START)

    San Antonio, Texas, 78229, United States

  • South Texas Accelerated Research Therapeutics (START) Midwest

    Grand Rapids, Michigan, 49546, United States

  • Universitätsspital Zürich, Dermatologische Klinik

    Zurich, 8058, Switzerland

Conditions

Explore the condition pages connected to this study.